Clinical Review

Atypical hyperplasia of the breast: Cancer risk-reduction strategies

Author and Disclosure Information

 

References


Most women will not develop breast malignancy
As Hartmann and colleagues point out, all is not dire once a woman is diagnosed with atypical hyperplasia of the breast. In most of these women, breast cancer will not develop—and if it does develop, it may occur at an age when mortality from other causes is more likely than from breast cancer. In this respect, women with atypical hyperplasia of the breast are different from carriers of BRCA mutations. Although women with atypical hyperplasia as well as mutation carriers are both at high lifetime risk for breast cancer, breast malignancies occur at an earlier age in mutation carriers. Accordingly, as the authors of this special report advise, in general, a diagnosis of atypical hyperplasia should not be considered an indication for risk-reducing bilateral mastectomy.


Share your thoughts on this article! Send your Letter to the Editor to rbarbieri@frontlinemedcom.com. Please include your name and the city and state in which you practice.

Pages

Recommended Reading

A quarter of women with dense breasts at high interval cancer risk
MDedge ObGyn
ACOG spells out risk assessment for hereditary cancer syndromes
MDedge ObGyn
Anastrozole provides alternative option for DCIS
MDedge ObGyn
ASCO: Precision medicine initiatives take wing
MDedge ObGyn
Three bisphosphonates found on par in early breast cancer
MDedge ObGyn
Advanced breast cancer: paclitaxel bests nab-paclitaxel, ixabepilone
MDedge ObGyn
ASCO: Adjuvant denosumab halves fracture risk for breast cancer patients on AIs
MDedge ObGyn
Obesity boosts postmenopausal breast cancer risk
MDedge ObGyn
VIDEO: Consider cost in anastrozole vs. tamoxifen for DCIS
MDedge ObGyn
Insurance, location, income drive breast cancer surgery choices
MDedge ObGyn

Related Articles